Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Access to Cabazitaxel in mHRPC
NCT01254279Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2010
- Primary completion
- Dec 2014
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of cabazitaxel ginsenoside liposome injection in prostate cancer (PCa), sponsored by Sanofi. Started Dec 2010; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01254279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01254279.